Batchimeg Usukhbayar
MSc, PhD (TMM)
Biobanking Lead
I was qualified at the Health Sciences University of Mongolia and followed up with some research fellowships abroad. Since moving to the UK, I started working at the Department of Medical Oncology, Oxford University since 2007. Later I joined Professor Vyas' group to oversee the expanding Haematopoietic cell Biobank, which was central to the research programme in the Vyas Lab and subsequently joined Therapy Acceleration Laboratory.
Recent publications
Rapid clonal selection within early hematopoietic cell compartments presages the outcome of ivosidenib combination therapy.
Journal article
Turkalj S. et al, (2026), Blood, 147, 613 - 632
Selective advantage of mutant stem cells in human clonal hematopoiesis is associated with attenuated response to inflammation and aging.
Journal article
Jakobsen NA. et al, (2024), Cell Stem Cell, 31, 1127 - 1144.e17
Selective advantage of mutant stem cells in clonal hematopoiesis occurs by attenuating the deleterious effects of inflammation and aging
Preprint
Jakobsen NA. et al, (2023)
Oncogenic Gata1 causes stage-specific megakaryocyte differentiation delay.
Journal article
Juban G. et al, (2021), Haematologica, 106, 1106 - 1119
Sensitive, rapid diagnostic test for transient abnormal myelopoiesis and myeloid leukemia of Down syndrome.
Journal article
Cruz Hernandez D. et al, (2020), Blood, 136, 1460 - 1465